MedTrace Logo

Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

NCT03138525 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2021-01-27

No results posted yet for this study

Summary

The purpose of this study is to assess effects of B cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before the infusions at 6 and 12 months. The effects on the immune system will be assessed by performing transcriptome profiling of immune cells, measuring serum levels of microRNAs, and analyzing serum autoantibody immune signatures using antigen arrays. In addition, blood will be collected once from a group of healthy individuals to serve as controls.

Conditions

Interventions

OTHER

Blood sampling (MS)

Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.

OTHER

Blood sampling (controls)

Blood samples will be collected once at enrollment.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Howard L Weiner, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-20
Primary Completion
2019-12-20
Completion
2019-12-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138525 on ClinicalTrials.gov